JP2005513000A - Psp−94:高カルシウム血症及び骨転移の治療のための使用 - Google Patents

Psp−94:高カルシウム血症及び骨転移の治療のための使用 Download PDF

Info

Publication number
JP2005513000A
JP2005513000A JP2003541867A JP2003541867A JP2005513000A JP 2005513000 A JP2005513000 A JP 2005513000A JP 2003541867 A JP2003541867 A JP 2003541867A JP 2003541867 A JP2003541867 A JP 2003541867A JP 2005513000 A JP2005513000 A JP 2005513000A
Authority
JP
Japan
Prior art keywords
psp
pthrp
animals
tumor
tumors
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2003541867A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005513000A5 (cg-RX-API-DMAC7.html
Inventor
シャファート・アメド・ラバーニ
ニコラス・シュキール
チャンドラ・ジェイ・パンチャル
クリストファー・ニューマン
Original Assignee
プロシオン バイオファーマ インク.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by プロシオン バイオファーマ インク. filed Critical プロシオン バイオファーマ インク.
Publication of JP2005513000A publication Critical patent/JP2005513000A/ja
Publication of JP2005513000A5 publication Critical patent/JP2005513000A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57555—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the prostate
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/84—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving inorganic compounds or pH
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/575—Hormones
    • G01N2333/635—Parathyroid hormone (parathormone); Parathyroid hormone-related peptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/04—Endocrine or metabolic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Inorganic Chemistry (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
JP2003541867A 2001-11-08 2002-11-08 Psp−94:高カルシウム血症及び骨転移の治療のための使用 Pending JP2005513000A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CA002361736A CA2361736A1 (en) 2001-11-08 2001-11-08 Psp 94: use for treatment of hypercalcemia and bone metastasis
PCT/CA2002/001737 WO2003039576A1 (en) 2001-11-08 2002-11-08 Psp-94: use for treatment of hypercalcemia and bone metastasis

Publications (2)

Publication Number Publication Date
JP2005513000A true JP2005513000A (ja) 2005-05-12
JP2005513000A5 JP2005513000A5 (cg-RX-API-DMAC7.html) 2005-12-22

Family

ID=4170464

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2003541867A Pending JP2005513000A (ja) 2001-11-08 2002-11-08 Psp−94:高カルシウム血症及び骨転移の治療のための使用

Country Status (6)

Country Link
US (1) US20030119744A1 (cg-RX-API-DMAC7.html)
EP (1) EP1441756A1 (cg-RX-API-DMAC7.html)
JP (1) JP2005513000A (cg-RX-API-DMAC7.html)
AU (1) AU2002340681B2 (cg-RX-API-DMAC7.html)
CA (1) CA2361736A1 (cg-RX-API-DMAC7.html)
WO (1) WO2003039576A1 (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050148514A1 (en) * 2003-09-26 2005-07-07 Panchal Chandra J. Method and composition for treatment of angiogenesis
CA2441695A1 (en) * 2003-09-26 2005-03-26 Unknown Regulation of matrix metalloproteinases by psp94 family members
CA2567901A1 (en) * 2004-06-01 2005-12-15 Ambrilia Biopharma Inc. Method and composition for treating angiogenesis and for preventing cancer progression and metastasis comprising a prostate secretory protein (psp94) family member
CA2502479A1 (en) * 2004-12-01 2006-06-01 Procyon Biopharma Inc. Laminin receptor binding molecule
AU2019370565A1 (en) * 2018-11-02 2021-06-24 Ampersand Biopharmaceuticals, Inc. Management of risk of cation overload and electrolyte imbalance with topically applied buffers

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5428011A (en) * 1992-06-16 1995-06-27 Procyon Biopharma, Inc. Pharmaceutical preparations for inhibiting tumours associated with prostate adenocarcinoma
CA2355334A1 (en) * 2000-10-16 2002-04-16 Procyon Biopharma Inc. Pharmaceutical preparations and methods for inhibiting tumors
US20050026833A1 (en) * 2001-11-08 2005-02-03 Rabbani Shafaat Ahmed PSP-94: use for treatment of hypercalcemia and bone metastasis

Also Published As

Publication number Publication date
EP1441756A1 (en) 2004-08-04
WO2003039576A1 (en) 2003-05-15
US20030119744A1 (en) 2003-06-26
AU2002340681B2 (en) 2007-09-13
CA2361736A1 (en) 2003-05-08

Similar Documents

Publication Publication Date Title
US8551951B2 (en) Pharmaceutical preparations and methods for inhibiting tumors
JP6715856B2 (ja) 膵臓がんおよびその他のがんに対する免疫療法において使用するための新規ペプチドおよびペプチドの組み合わせ
ES2860798T3 (es) Nuevos péptidos y nuevas combinaciones de péptidos y de soportes para el uso en la inmunoterapia contra el carcinoma colorrectal y otros tipos de cáncer
JP6675394B2 (ja) 疾患及び障害の治療のためにインターロイキン−10を使用する方法
RS62448B1 (sr) Novi peptidi i kombinacija peptida za upotrebu u imunoterapiji protiv hepatocelularnog karcinoma (hcc) i drugih malignih tumora
UA126787C2 (uk) Пептид, нуклеїнова кислота, вектор експресії, клітина-хазяїн, спосіб отримання пептиду, активовані цитотоксичні t-лімфоцити та спосіб їх отримання та застосування, спосіб лікування раку
JP7478718B2 (ja) 膵臓がんおよびその他のがんに対する免疫療法において使用するための新規ペプチドおよびペプチドの組み合わせ
US10611798B2 (en) PAR1 and PAR2 c-tail peptides and peptide mimetics
JPWO2018207866A1 (ja) がん治療効果の検査方法及び免疫応答誘導用組成物
CN101437399A (zh) 调节免疫应答的方法和试剂
AU2002340681B2 (en) PSP-94: Use for treatment of hypercalcemia and bone metastasis
WO2001093897A9 (en) Angiostatin and endostatin binding proteins and methods of use
US8252545B2 (en) Peptides of a melanoma antigen and their use in diagnostic, prophylactic, and therapeutic methods
AU2002340681A1 (en) PSP-94: Use for treatment of hypercalcemia and bone metastasis
US20050026833A1 (en) PSP-94: use for treatment of hypercalcemia and bone metastasis
AU2012380681A1 (en) Novel melanoma antigen peptide and uses thereof
AU2007246192A1 (en) PSP-94: use for treatment of hypercalcemia and bone metastasis
CA2407548A1 (en) Psp94: use for treatment of hypercalcemia and bone metastasis
ES2351783T3 (es) Preparaciones farmacéuticas y procedimientos para la inhibición de tumores.
US8129349B2 (en) Treatment of disease by inducing cell apoptosis
CA2143945A1 (en) A method for the detection and treatment of prostate disease
WO1994006935A9 (en) A method for the detection and treatment of prostate disease
US20120141506A1 (en) Treatment of non-proliferative cystic disease
US20050148514A1 (en) Method and composition for treatment of angiogenesis
US20080200393A1 (en) Method and Composition For Treating Angiogenesis and For Preventing Cancer Progression and Metastasis Comprising a Prostate Secretory Protein (Psp94) Family Member

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20051102

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20090127

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20090623